This article discusses key strategies for managing multiple sclerosis, including immunomodulatory therapies, disease-modifying treatments like Gilenya, Teriflunomide, and Dimethyl Fumarate. It emphasizes the importance of early diagnosis, personalized treatment plans, and the role of FDA-approved medications in reducing relapses and delaying disease progression to improve patients' quality of life.

Strategies for Effective Management of Multiple Sclerosis

Managing multiple sclerosis involves targeting the immune system disorder while addressing symptom relief. Immunomodulatory treatments (IMTs) help reduce relapse rates and slow disease development. These disease-modifying therapies are mainly aimed at relapse-remitting MS to change its trajectory. Patients with relapsing MS typically receive FDA-approved medications to control symptoms and prevent further attacks.

Treatment usually starts at diagnosis or following a clinical event. Ongoing use depends on how well the patient responds, side effects, and newer options available. Discontinuation may occur if adverse effects arise or better therapies emerge. For example, Gilenya, approved by the FDA in 2010, is an oral medication that greatly reduces relapses and delays progression.

Additional FDA-approved options include Teriflunomide, approved in 2012, which slows disease progression and is more effective at higher doses. In 2013, Dimethyl Fumarate was approved to protect myelin and prevent immune attacks, acting similarly to antioxidants. Since MS currently has no cure, treatments focus on slowing progression and enhancing quality of life.